Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2007-07-24
2007-07-24
O'Hara, Eileen B. (Department: 1646)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C530S388100, C530S388150, C530S388800, C530S391900
Reexamination Certificate
active
10172317
ABSTRACT:
Isolated human monoclonal antibodies which specifically bind to human EGFR, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
REFERENCES:
patent: 4943533 (1990-07-01), Mendelsohn et al.
patent: 4954617 (1990-09-01), Fanger et al.
patent: 5218090 (1993-06-01), Connors
patent: 5459061 (1995-10-01), Sato et al.
patent: 5470571 (1995-11-01), Herlyn et al.
patent: 5614488 (1997-03-01), Bacha
patent: 5643759 (1997-07-01), Pfreundschuh
patent: 5705157 (1998-01-01), Greene
patent: 5708156 (1998-01-01), Ilekis
patent: 5770195 (1998-06-01), Hudziak et al.
patent: 5844093 (1998-12-01), Kettleborough et al.
patent: 5874299 (1999-02-01), Lonberg et al.
patent: 5906820 (1999-05-01), Bacha
patent: 6217866 (2001-04-01), Schlessinger et al.
patent: 6235883 (2001-05-01), Jakobovits et al.
patent: 6538114 (2003-03-01), Persson et al.
patent: 6680209 (2004-01-01), Buechler et al.
patent: 2002/0004587 (2002-01-01), Miller et al.
patent: 0 667 165 (1995-08-01), None
patent: 586 002 (2000-01-01), None
patent: 706 799 (2001-11-01), None
patent: 1 170 011 (2002-01-01), None
patent: WO 85/50433 (1985-05-01), None
patent: WO 85/50433 (1985-05-01), None
patent: WO 95/16037 (1995-06-01), None
patent: WO 95/20045 (1995-07-01), None
patent: WO 98/50433 (1998-11-01), None
patent: WO 98/50433 (1998-11-01), None
patent: WO 00/37025 (2000-06-01), None
patent: WO 01/09187 (2001-02-01), None
patent: WO 01/25492 (2001-04-01), None
patent: WO-01/88138 (2001-11-01), None
patent: WO-02/11677 (2002-02-01), None
Modjtahedi, H. and Dean, C. (1994). The receptor for EGF and its ligands: Expression, prognostic value and target for therapy in cancer (Review). International Journal of Oncology 4:277-296.
Yang, X-D et al. (1999). Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Research 59:1236-1243.
Da Costa et al. (1997). The role of the mouse macrophage scavenger receptor in myelin phagocytosis. European Journal of Neuroscience 9:2650-2657.
Rudikoff et al. (1982). Single amino acid substitution altering antigen-binding specificity. Proc. Natl. Acad. Sci. USA. 79:1979-1983.
Genmabs HuMax-EGFr Eradicates Tumors in Mouse Cancer Studies. Retrieved from the Internet: www.presseportal.de/story.htx?nr=256717&firmaid=17265. Retrieved on Jun. 13, 2001.
Heitner, et al. Selection of cell binding and internalizing epidermal growth factor receptor antibodies from a phage display library. J Immunol Methods. Feb. 1, 2001;248(1-2):17-30.
Masui, et al. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res. Mar. 1984;44(3):1002-7.
Yang, et al. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res. Mar. 15, 1999;59(6):1236-43.
Elsasser, et al. (1999). Preclinical studies combining bispecific antibodies with cytokine-stimulated effector cells for immunotherapy of renal cell carcinoma. Anticancer Research 19:1525-1528.
Stadick, et al. (2002). Epidermal growth factor receptor and G250: Useful target antigens for antibody mediated cellular cytotoxicity against renal cell carcinoma? The Journal of Urology 167:707-712.
Van Spriel, et al. (2000). Immunotherapeutic perspective for bispecific antibodies. Immunology Today 21:8: 391-97.
Wang et al. Human Cytomegalovirus Receptor: HCMV Infection of HEL Cell is EGF Receptor Dependent, Poster Presentation at 26thInternational Herpes Workshop, Jul. 28-Aug. 3, 2001, Germany.
Wang et al. Receptor for Human Cytomegalovirus: HCMV Infection of HEL and HUVE Cells is EGF Receptor Dependent, Poster Presentation at 26thInternational Herpes Workshop, Jul. 28-Aug. 3, 2001, Germany.
Wang, X. et al. “Epidermal growth factor receptor is a cellular receptor for human cytomegalovirus.”Nature.Jul. 24, 2003; 424(6947):456-61.
Albanell, Joan, et al., “Activated Extracellular Signal-regulated Kinases: Association with Epidermal Growth Factor Receptor/Transforming Growth Factor α Expression in Head and Neck Squamous Carcinoma and Inhibition by Anti-Epidermal Growth Factor Receptor Treatments,”Cancer Research,vol. 61:6500-6510 (2001).
Baselga, J., “The EGFR as a target for anticancer therapy—focus on cetuximab,”European Journal of Cancer,vol. 37:S16-S22 (2001).
Baselga, José, “Monoclonal antibodies directed at growth factor receptors,”Ann. Oncol.,vol. 11(Suppl. 3):187-190 (2000).
Baselga, José, “New Therapeutic Agents Targeting the Epidermal Growth Factor Receptor,”Journal of Clinical Oncology,vol. 18(21s):54s-59s (2000).
Bastholt, L., et al., “A novel fully human monoclonal antibody against Epidermal Growth Factor Receptor (EGFR), First clinical and FDG-PET imaging results from a phase I/II trial conducted by the Danish Head and Neck Cancer Study Group (DAHANCA) in patients with squamous cell carcinoma of the head and neck (SCCHN),” found online at: http://meeting,jco.org/cgi/content/abstract/23/16—suppl/5530.
Bastholt, L., et al., “HuMax-EGFr, a Novel Fully Human Monoclonal Antibody against EGFr Safety and Pharmacokinetics in Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN),”.
Bier, Henning, et al., “Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck,”Cancer Immunoll Immunother.,vol. 46:167-173 (1998).
Bishop, Philippe C., et al., “Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family,”Oncogene,vol. 21:119-127 (2002).
Bunn, Paul A., et al., “Epidermal Growth Factor Receptor Expression, Signal Pathway, and Inhibitors in Non-Small Cell Lung Cancer,”Seminars in Oncology,vol. 29(5, Suppl. 4):38-44 (2002).
Ciardiello, Fortunato, et al., “Anti-epidermal growth factor receptor drugs in cancer therapy,”Expert Opin. Investig. Drugs,vol. 11(6):755-768 (2002).
Ciardiello, Fortunato, et al., “A Novel Approach in the Treatment of Cancer: Targeting the Epidermal Growth Factor Receptor,”Clinical Cancer Research,vol. 7:2958-2970 (2001).
Genmab, “Genmab Presents New Humax-CD20 and Humax-EFGr Pre-Clinical Data,”Genmab,Release No. Apr. 2003.
Genmab, “Genmab's HuMax-EGFr Eradicates Tumors in Mouse Cancer Studies HuMax-EGFr Highly Effective,”Genmab,Release No. 21.
Genmab, “Genmab Announces Positive Phase I/II Humax™-EGFR Safety Data,”GenmabRelease No. 66/2004.
Genmab, “Genmab Announces Encouraging Efficacy Data from Humax-EGFR Phase I/II Trial in Head and Neck Cancer,”Genmab,Release No. 74/2004.
Genmab, “Genmab Presents Additional Humax®-EGFR Phase I/II Efficacy Data at ASCO Conference,”Genmab,Release No. 23/2005.
Khuri, Fadlo R., et al., “Treatment of Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Current Status and Future Directions,”Seminars in Oncology,vol. 27(4, Suppl. 8):25-33 (2000).
van Bueren, J.J., L., et al., “Impact of receptor-mediated antibody internationalization on the dose-effect relationship of a therapeutic mAb against EGFR,”Joint Annual Meeting of the German and Dutch Societies for Immunology(JAMI) /Immunology,vol. 209:367-368 (2004).
van Zoelen, E.J.J., et al., “Rational Design for the Development of Epidermal Gr
Gerritsen Arnout F.
Halk Edward
van de Winkel Jan G. J.
van Dijk Marcus A.
Genmab A/S
Lahive & Cockfield, LLP.
O'Hara Eileen B.
Remillard, Esquire Jane E.
Xie Xiaozhen
LandOfFree
Human monoclonal antibodies to epidermal growth factor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human monoclonal antibodies to epidermal growth factor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human monoclonal antibodies to epidermal growth factor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3765735